221 related articles for article (PubMed ID: 29197156)
21. Efficacy and safety of recombinant factor VIII products in patients with hemophilia A.
Musso R
Drugs Today (Barc); 2008 Oct; 44(10):735-50. PubMed ID: 19137127
[TBL] [Abstract][Full Text] [Related]
22. Production processes of licensed recombinant factor VIII preparations.
Boedeker BG
Semin Thromb Hemost; 2001 Aug; 27(4):385-94. PubMed ID: 11547361
[TBL] [Abstract][Full Text] [Related]
23. Association of the factor VIII light chain with von Willebrand factor.
Lollar P; Hill-Eubanks DC; Parker CG
J Biol Chem; 1988 Jul; 263(21):10451-5. PubMed ID: 3134349
[TBL] [Abstract][Full Text] [Related]
24. Comparative analysis of marketed factor VIII products: recombinant products are not alike vis-a-vis soluble protein aggregates and subvisible particles.
Anzengruber J; Lubich C; Prenninger T; Gringeri A; Scheiflinger F; Reipert BM; Malisauskas M
J Thromb Haemost; 2018 Jun; 16(6):1176-1181. PubMed ID: 29665242
[TBL] [Abstract][Full Text] [Related]
25. Non-clinical pharmacokinetics and pharmacodynamics of rVIII-SingleChain, a novel recombinant single-chain factor VIII.
Zollner S; Raquet E; Claar P; Müller-Cohrs J; Metzner HJ; Weimer T; Pragst I; Dickneite G; Schulte S
Thromb Res; 2014 Jul; 134(1):125-31. PubMed ID: 24814969
[TBL] [Abstract][Full Text] [Related]
26. Factor VIII assay variability in postinfusion samples containing full length and B-domain deleted FVIII.
Kitchen S; Jennings I; Makris M; Kitchen DP; Woods TA; Walker ID
Haemophilia; 2016 Sep; 22(5):806-12. PubMed ID: 27217329
[TBL] [Abstract][Full Text] [Related]
27. The new albumin-free recombinant factor VIII concentrates for treatment of hemophilia: do they represent an actual incremental improvement?
Josephson CD; Abshire T
Clin Adv Hematol Oncol; 2004 Jul; 2(7):441-6. PubMed ID: 16163220
[TBL] [Abstract][Full Text] [Related]
28. Autoantibody to factor VIII that has less reactivity to factor VIII/von Willebrand factor complex.
Amano K; Arai M; Koshihara K; Suzuki T; Kagawa K; Nishida Y; Fukutake K
Am J Hematol; 1995 Aug; 49(4):310-7. PubMed ID: 7639276
[TBL] [Abstract][Full Text] [Related]
29. Evolution of recombinant factor VIII safety: KOGENATE and Kogenate FS/Bayer.
Lusher JM; Scharrer I
Int J Hematol; 2009 Nov; 90(4):446-454. PubMed ID: 19882376
[TBL] [Abstract][Full Text] [Related]
30. Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor.
Suzuki T; Arai M; Amano K; Kagawa K; Fukutake K
Thromb Haemost; 1996 Nov; 76(5):749-54. PubMed ID: 8950785
[TBL] [Abstract][Full Text] [Related]
31. [Population pharmacokinetics of two recombinant human coagulation factor Ⅷ preparations in patients with hemophilia A].
Hua BL; Chelle P; Yeung C; Gu J; Zhao YQ; Iorio A
Zhonghua Xue Ye Xue Za Zhi; 2019 Aug; 40(8):673-677. PubMed ID: 31495135
[No Abstract] [Full Text] [Related]
32. Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII.
Zollner SB; Raquet E; Müller-Cohrs J; Metzner HJ; Weimer T; Pragst I; Dickneite G; Schulte S
Thromb Res; 2013 Aug; 132(2):280-7. PubMed ID: 23830969
[TBL] [Abstract][Full Text] [Related]
33. Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis.
Peyvandi F; Cannavò A; Garagiola I; Palla R; Mannucci PM; Rosendaal FR;
J Thromb Haemost; 2018 Jan; 16(1):39-43. PubMed ID: 29080391
[TBL] [Abstract][Full Text] [Related]
34. Continuous infusion during total joint arthroplasty in Japanese haemophilia A patients: comparison study among two recombinants and one plasma-derived factor VIII.
Takedani H
Haemophilia; 2010 Sep; 16(5):740-6. PubMed ID: 20398072
[TBL] [Abstract][Full Text] [Related]
35. Relationships between factor VIII:Ag and factor VIII in recombinant and plasma-derived factor VIII concentrates.
Lin Y; Yang X; Chevrier MC; Craven S; Barrowcliffe TW; Lemieux R; Ofosu FA
Haemophilia; 2004 Sep; 10(5):459-69. PubMed ID: 15357771
[TBL] [Abstract][Full Text] [Related]
36. Novel investigations on the protective role of the FVIII/VWF complex in inhibitor development.
Mannucci PM; Shi Q; Bonanad S; Klamroth R
Haemophilia; 2014 Sep; 20 Suppl 6():2-16. PubMed ID: 24975700
[TBL] [Abstract][Full Text] [Related]
37. ReFacto and Advate: a single-dose, randomized, two-period crossover pharmacokinetics study in subjects with haemophilia A.
Di Paola J; Smith MP; Klamroth R; Mannucci PM; Kollmer C; Feingold J; Kessler C; Pollmann H; Morfini M; Udata C; Rothschild C; Hermans C; Janco R
Haemophilia; 2007 Mar; 13(2):124-30. PubMed ID: 17286764
[TBL] [Abstract][Full Text] [Related]
38. A new method measuring the interaction between von Willebrand factor and coagulation factor VIII.
Karlman M; Holmström M; Wiman B
Thromb Res; 2011 Jan; 127(1):47-50. PubMed ID: 21094987
[TBL] [Abstract][Full Text] [Related]
39. Area under the curve: Comparing the value of factor VIII replacement therapies in haemophilia A.
Persson S; Berndt C; Engstrand S; Trinczek A; Carlsson KS; Berntorp E
Haemophilia; 2023 Jan; 29(1):145-155. PubMed ID: 36445343
[TBL] [Abstract][Full Text] [Related]
40. Clotting and chromogenic factor VIII assay variability in post-infusion and spiked samples containing full-length recombinant FVIII or recombinant factor VIII Fc fusion protein (rFVIIIFc).
Kitchen S; Jennings I; Makris M; Kitchen DP; Woods TAL; Walker ID
Int J Lab Hematol; 2019 Apr; 41(2):176-183. PubMed ID: 30556650
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
